A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.

"Canadians wait, on average, more than 65 weeks longer for access to new medicines than Europeans and 90 weeks more than ...

Health Canada says it is reviewing nine submissions for generic versions of popular weight loss medications that pharmaceutical experts say could bring down the price. The submissions in Canada are ...

Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.

The NCATA’s Athlete of the Week award is calling Matthew Knight Arena home for the first time in 2026. Base/tumbler Ashlyn Parlett took... In recent years, a growing number of Americans have found ...

Jane Fletcher receives funding from CANTRAIN (Canadian Institutes of Health Research) and Alberta Innovates. David Campbell receives funding from the Canadian Institutes of Health Research, Diabetes ...

U.S. consumers pay higher prices for drugs to help pay for research and development, about 2.78 times higher than in ...

Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer's disease, Canada's Drug Agency says in its draft recommendation.

Add Yahoo as a preferred source to see more of our stories on Google. Ozempic, pictured in May 2022, contains semaglutide, which is used to treat diabetes and obesity. Health Canada says it is ...